Vident Investment Advisory, LLC Allogene Therapeutics, Inc. Transaction History

Vident Investment Advisory, LLC

$0
Q3 2023

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$4.92 - $8.21 $14,331 - $23,915	-2,913 Reduced 2.8%	101,213 $499,000
Q4 2022 Feb 14, 2023	BUY	$5.62 - $11.11 $219,151 - $433,234	38,995 Added 59.87%	104,126 $654,000
Q3 2022 Nov 14, 2022	SELL	$10.32 - $17.28 $71,053 - $118,972	-6,885 Reduced 9.56%	65,131 $702,000
Q2 2022 Aug 15, 2022	SELL	$6.78 - $12.28 $36,889 - $66,815	-5,441 Reduced 7.02%	72,016 $821,000
Q1 2022 May 16, 2022	BUY	$7.65 - $15.29 $98,761 - $197,393	12,910 Added 20.0%	77,457 $706,000
Q4 2021 Feb 14, 2022	BUY	$13.13 - $24.52 $104,619 - $195,375	7,968 Added 14.08%	64,547 $963,000
Q3 2021 Nov 12, 2021	SELL	$21.01 - $27.64 $84,922 - $111,720	-4,042 Reduced 6.67%	56,579 $1.45 Million
Q2 2021 Aug 13, 2021	BUY	$23.49 - $35.8 $24,828 - $37,840	1,057 Added 1.77%	60,621 $1.58 Million
Q4 2020 Feb 08, 2021	BUY	$25.24 - $43.45 $737,714 - $1.27 Million	29,228 Added 96.35%	59,564 $1.5 Million
Q3 2020 Nov 12, 2020	SELL	$32.38 - $44.96 $196,546 - $272,907	-6,070 Reduced 16.67%	30,336 $1.14 Million
Q2 2020 Jul 17, 2020	SELL	$18.39 - $54.04 $337,309 - $991,201	-18,342 Reduced 33.5%	36,406 $1.56 Million
Q1 2020 May 12, 2020	SELL	$18.22 - $28.25 $24,086 - $37,346	-1,322 Reduced 2.36%	54,748 $1.06 Million
Q4 2019 Feb 11, 2020	BUY	$24.82 - $31.4 $80,590 - $101,955	3,247 Added 6.15%	56,070 $1.46 Million
Q3 2019 Nov 13, 2019	SELL	$26.11 - $32.99 $39,399 - $49,781	-1,509 Reduced 2.78%	52,823 $1.44 Million
Q2 2019 Aug 12, 2019	SELL	$25.56 - $31.09 $127,748 - $155,387	-4,998 Reduced 8.42%	54,332 $1.46 Million
Q1 2019 May 08, 2019	SELL	$24.82 - $32.54 $33,556 - $43,994	-1,352 Reduced 2.23%	59,330 $1.72 Million
Q4 2018 Feb 14, 2019	BUY	$22.5 - $33.3 $1.37 Million - $2.02 Million	60,682 New	60,682 $1.63 Million

Others Institutions Holding ALLO

# of Institutions

165

Shares Held

134M

Call Options Held

59.4K

Put Options Held

113K

View Full List

About Allogene Therapeutics, Inc.

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $265M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

More about ALLO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vident Investment Advisory, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Vident Investment Advisory, LLC with notifications on news.

Account